Holen Sie sich die Stockscreener-App
12.16
2.56%
-0.315
Handel nachbörslich:
12.18
0.015
+0.12%
Schlusskurs vom Vortag:
$12.48
Offen:
$12.38
24-Stunden-Volumen:
579.91K
Relative Volume:
0.72
Marktkapitalisierung:
$779.04M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.6049
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
-10.59%
1M Leistung:
+4.38%
6M Leistung:
+57.11%
1J Leistung:
+42.22%
1-Tages-Spanne:
$11.92
$12.70
1-Wochen-Bereich:
$11.92
$14.51
52-Wochen-Spanne:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
12.18 | 798.23M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.25 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.32 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.55 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.46 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com Nigeria
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference - Stock Titan
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference - MarketBeat
Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity - MarketBeat
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil - Trefis
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference - MarketBeat
Insider Buying: Briggs Morrison Acquires 20,000 Shares of Arvinas Inc (ARVN) - GuruFocus
ARVN: Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024 - TradingView
Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Vanguard Group Inc. Trims Position in Arvinas, Inc. $ARVN - MarketBeat
Institution Moves: What dividend growth rate does Arvinas Inc offer2025 Macro Impact & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Why analysts remain bullish on Arvinas Inc. stock2025 Trading Recap & Accurate Buy Signal Alerts - Naître et grandir
Piper Sandler reiterates Arvinas stock rating on platform validation By Investing.com - Investing.com India
Piper Sandler reiterates Arvinas stock rating on platform validation - Investing.com South Africa
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Yahoo Finance
Discipline and Rules-Based Execution in ARVN Response - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Given New $18.00 Price Target at Citigroup - MarketBeat
Citigroup Raises Price Target for Arvinas (ARVN) to $18.00 | ARV - GuruFocus
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - MarketBeat
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Insider Monkey
Arvinas (NASDAQ:ARVN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
11 Best Cancer Stocks to Invest In Now - Insider Monkey
TD Cowen Health Care Conference - marketscreener.com
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley - The Globe and Mail
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations - DirectorsTalk Interviews
HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus - MSN
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News
Teel Randy, president and CEO of Arvinas, sells $58k in stock - Investing.com India
Arvinas CSO Cacace sells $43,885 in stock to cover tax obligations - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com - Investing.com South Africa
Teel Randy, president and CEO of Arvinas, sells $58k in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock - Investing.com
Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares - MarketBeat
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares - MarketBeat
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
5 Analysts Assess Arvinas: What You Need To Know - Benzinga
Arvinas (NASDAQ:ARVN) Trading Up 9%Still a Buy? - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler Raises Price Target on Arvinas (ARVN) to $20.00 | - GuruFocus
ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arvinas Inc-Aktie (ARVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Houston John G | Director |
Feb 27 '26 |
Sale |
13.21 |
35,297 |
466,154 |
1,122,183 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):